Literature DB >> 33683499

Synthetic Receptor-Based Targeting Strategies to Improve Tumor Drug Delivery.

Susheel Kumar Nethi1, Shubhmita Bhatnagar2, Swayam Prabha3,4.   

Abstract

Heterogeneity in tumor expression as well as expression in normal tissues of various targets limit the usefulness of current ligand-based active targeting approaches. Incorporation of synthetic receptors, which can be recognized by delivery systems engineered to present specific functional groups on the surface, is a novel approach to improve tumor targeting. Alternatively, introduction of synthetic functionalities on cellular carriers can also enhance tumor targeting. We review various strategies that have been utilized for the introduction of synthetic targets in tumor tissues. The introduction of synthetic functional groups in the tumor through improved strategies is anticipated to result in improved target specificity and reduced heterogeneity in target expression.

Entities:  

Keywords:  engineered cells; mesenchymal stem cells; metabolic glycoengineering; synthetic targets; tumor targeting

Mesh:

Substances:

Year:  2021        PMID: 33683499     DOI: 10.1208/s12249-021-01919-w

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  82 in total

Review 1.  Hitting the Target: How T Cells Detect and Eliminate Tumors.

Authors:  Anthony E Zamora; Jeremy Chase Crawford; Paul G Thomas
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.

Authors:  Uma Prabhakar; Hiroshi Maeda; Rakesh K Jain; Eva M Sevick-Muraca; William Zamboni; Omid C Farokhzad; Simon T Barry; Alberto Gabizon; Piotr Grodzinski; David C Blakey
Journal:  Cancer Res       Date:  2013-02-19       Impact factor: 12.701

Review 3.  Nanoparticle-based targeted drug delivery.

Authors:  Rajesh Singh; James W Lillard
Journal:  Exp Mol Pathol       Date:  2009-01-07       Impact factor: 3.362

Review 4.  Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?

Authors:  Yuko Nakamura; Ai Mochida; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2016-09-02       Impact factor: 4.774

Review 5.  Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy.

Authors:  Savita Bisht; Amarnath Maitra
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2009 Jul-Aug

Review 6.  Nanotechnology-based approaches in anticancer research.

Authors:  Nasimudeen R Jabir; Shams Tabrez; Ghulam Md Ashraf; Shazi Shakil; Ghazi A Damanhouri; Mohammad A Kamal
Journal:  Int J Nanomedicine       Date:  2012-08-09

Review 7.  Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.

Authors:  Hiroshi Maeda
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

Review 8.  Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery.

Authors:  Bo Zhang; Yu Hu; Zhiqing Pang
Journal:  Front Pharmacol       Date:  2017-12-22       Impact factor: 5.810

9.  Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies.

Authors:  Jiayin Shen; Yingwen Hu; Karson S Putt; Sunil Singhal; Haiyong Han; Daniel W Visscher; Linda M Murphy; Philip S Low
Journal:  Oncotarget       Date:  2017-12-15

Review 10.  Progress and challenges towards targeted delivery of cancer therapeutics.

Authors:  Daniel Rosenblum; Nitin Joshi; Wei Tao; Jeffrey M Karp; Dan Peer
Journal:  Nat Commun       Date:  2018-04-12       Impact factor: 14.919

View more
  1 in total

1.  National Institute for Pharmaceutical Technology & Education (NIPTE) Research and Perspective: Advances in Nanotechnology-Based Drug Delivery.

Authors:  Aliasger K Salem; Xiuling Lu
Journal:  AAPS PharmSciTech       Date:  2021-05-11       Impact factor: 4.026

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.